Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.97 - $72.83
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.49M
Market Cap
$8.86B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 06, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding188,637,680
10 Day Avg. Volume2,012,573
30 Day Avg. Volume2,494,619
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$68.67Price Target Upside46.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Growth DriversInvestments into the channel being made and further indication expansion/reimbursement wins are expected, which should drive meaningful growth.
Market PotentialMedicare coverage of EXAS's Oncodetect MRD assay offers potential revenue growth as the company expands beyond its core franchises.
Technological AdvantageExact Sciences is developing a PCR-based blood-based screening method for colorectal cancer, which may have advantages over sequencing-based tests such as cost and scalability.
Bears Say
Competitive PressureCompetition in the solid tumor MRD market is expected to increase, making it challenging for EXAS to capture market share.
Market ChallengesPatients already using NTRA Signatera are unlikely to switch to other assays, posing a commercial challenge for EXAS.
Market CompetitionExact Sciences has a steep hill to climb to compete against industry leaders Natera and Guardant Health.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $39.97 and its highest was $72.83 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $8.86B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Aug 06, 2025 which is in 4 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on May 01, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.165.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.13.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 188,637,680 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went up 9.309%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.67 (46.26% Upside)
$68.67 (46.26% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 948.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.78%
12-Months-Change
Fundamentals
Return on Equity
-36.89%
Trailing 12-Months
Asset Growth
-10.43%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Company Deck
EXAS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved profitability, and successful product launches, indicating a strong start to 2025. However, challenges with commercial payer coverage for new products and the impact of a severe flu season were noted.Read More>EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$68.67
▲(46.26%Upside)
Technical Analysis
Ownership Overview
1.05% Insiders
45.20% Mutual Funds
0.88% Other Institutional Investors
38.86% Public Companies and Individual Investors